Printer Friendly

LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME

 SAN DIEGO, Nov. 19 ~PRNewswire~ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) announced that its compound, TP-9201, has been shown by independent researchers to prevent blood clotting without increasing bleeding time in animal models of heart attack and thrombosis. Existing commercial treatments for prevention of blood clotting are known to increase the risk of bleeding. The findings on TP-9201, a synthetic RGD-containing peptide that blocks the IIb~IIIa receptors on platelets, were presented by two leading cardiovascular research groups this week at the 65th annual American Heart Association Meeting held in New Orleans.
 Dr. Herman K. Gold of the Massachusetts General Hospital and his associates demonstrated that TP-9201 was an effective inhibitor of platelet aggregation, an important component of the blood clotting process, in their animal model of heart attack treated with thrombolytic therapy. The data also indicate that TP-9201 enhanced the clot dissolving action of low doses of tissue plasminogen activator (tPA), a drug currently used to treat heart attacks. The ability to more rapidly open occluded blood vessels to the heart was observed with only a minor effect on bleeding time, a serious side effect of many drugs aimed at controlling platelet function.
 The second report, authored by Dr. Desire Collen of the University of Leuven in Belgium and his colleagues, demonstrated the superiority of TP-9201 in preventing occlusion in a thrombogenic blood vessel when compared to heparin, aspirin and another specific antagonist of the IIb~IIIa receptor. TP-9201 was the only compound to keep the blood vessel open during the entire course of the experiment in this in vivo model. In addition, TP-9201 again inhibited platelet-mediated clot formation without associated prolongation of bleeding time. The report concluded that "the data document a possible dissociation between anti-thrombotic and hemorrhagenic effects," and that TP-9201 "could constitute a preferred potential agent for the treatment of acute ischemic coronary syndromes."
 "Until now, experts have believed it was necessary to compromise the control of bleeding to prevent thrombosis," said Michael D. Pierschbacher, Ph.D., senior vice president and scientific director of Telios and a co-founder of the company. "These two animal studies show that this novel inhibitor of platelet aggregation not only enhances the effectiveness of thrombolytic therapy but can also maintain blood flow without increasing the risk of bleeding. This is the first time that this dissociation has been shown," Pierschbacher continued. "We feel that TP-9201 will set the standard to be met in the field of anti-thrombotic therapy."
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases, cardiovascular diseases and osteoporosis. TP-9201 is being developed by Telios to treat a variety of thrombotic disorders and the company plansto file an IND for the product in 1993.
 -0- 11~19~92 R
 ~CONTACT: Audrey D. Keane, director of corporate development of Telios Pharmaceuticals, 619-622-2615~
 (TLIO)


CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU:

KJ -- SD003 -- 3383 11~20~92 12:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1992
Words:513
Previous Article:MEDQUIST TO SELL AMBULATORY SURGERY CENTER
Next Article:WASHINGTON STATE DEPARTMENTS OF HEALTH, FISHERIES EXTEND RECREATIONAL RAZOR CLAM HARVESTING THROUGH DEC. 31
Topics:


Related Articles
THE JOURNAL TRANSFUSION PUBLISHES ARTICLE ON TREATMENT OF REFRACTORINESS TO PLATELET TRANSFUSION WITH IMRE CORPORATION'S PROSORBA COLUMN
TELIOS FILES IND FOR ANTI-THROMBOTIC PEPTIDE, TP-9201
JOURNAL ARTICLES REPORT UNIQUE SAFETY PROFILE AND PROPRIETARY STRUCTURE OF TELIOS' ANTI-THROMBOTIC PEPTIDE
PHASE I CLINICAL TRIAL AFFIRMS DISTINCTIVE SAFETY PROFILE OF TELIOS' PLATELET AGGREGATION INHIBITOR TP-9201
Integra LifeSciences Announces Patent Issued to Treat Thrombosis
Integra LifeSciences Awarded New TP-9201 Patent and New NIH Grant
SmithKline Beecham's Anticoagulant Argatroban is Now Available In the United States.
Novo Nordisk and the Chicago Cubs Partner with the National Hemophilia Foundation and the Hemophilia Foundation of Illinois to Raise Awareness Of...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters